Stockscreener 앱 받기
2.93
10.15%
0.27
시간 외 거래:
2.80
-0.13
-4.44%
전일 마감가:
$2.66
열려 있는:
$2.82
하루 거래량:
345.07K
Relative Volume:
2.75
시가총액:
$5.86M
수익:
$3.58M
순이익/손실:
$-11.33M
주가수익비율:
-0.2672
EPS:
-10.9665
순현금흐름:
$-9.75M
1주 성능:
+19.11%
1개월 성능:
-14.58%
6개월 성능:
-72.87%
1년 성능:
-75.38%
1일 변동 폭
$2.60
$3.00
1주일 범위
$2.45
$3.007
52주 변동 폭
$2.42
$24.90
Intelligent Bio Solutions Inc Stock (INBS) Company Profile
명칭
Intelligent Bio Solutions Inc
전화
646-790-5756
주소
135 W 41ST ST,, NEW YORK
Compare INBS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBS
Intelligent Bio Solutions Inc
|
2.93 | 5.32M | 3.58M | -11.33M | -9.75M | -10.97 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Intelligent Bio Solutions Inc 주식(INBS)의 최신 뉴스
Intelligent Bio : Investor DeckApril 2026 - marketscreener.com
Intelligent Bio Solutions (INBS) Launches Study to Enhance Drug Screening Speed - GuruFocus
Intelligent Bio Solutions Inc. Launches Validation Study to Achieve Sub-3-Minute Results in Roadside Drug Testing Technology - Quiver Quantitative
Fingerprint drug test aims for under-3-minute roadside results - Stock Titan
Intelligent Bio Solutions Updates Investor Presentation and Share Count - TipRanks
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
INBS completes penetration testing for FDA 510(k) submission By Investing.com - Investing.com India
Intelligent Bio Solutions (INBS) Enhances Security Ahead of FDA Submission - GuruFocus
Intelligent Bio Solutions Inc. Advances Fda 510(K) Submission And Completes Penetration Testing - marketscreener.com
INBS completes penetration testing for FDA 510(k) submission - Investing.com
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified - The Manila Times
No major security flaws found as Intelligent Bio readies FDA filing - Stock Titan
How cyclical is Intelligent Bio Solutions Incs revenue stream2026 Price Swings & Smart Money Movement Tracker - baoquankhu1.vn
INBS Stock Price, Quote & Chart | INTELLIGENT BIO SOLUTIONS IN (NASDAQ:INBS) - ChartMill
INBS Advances FDA Approval with Successful Initial Study - GuruFocus
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market - Bitget
Intelligent Bio Solutions Completes Clinical Cut-Off Study - TradingView — Track All Markets
INBS Stock Falls After Clinical Study Win: FDA Progress Fails To Lift Shares - Stocktwits
A fingerprint drug test moved closer to a U.S. launch after codeine study - Stock Titan
Published on: 2026-03-31 09:14:37 - baoquankhu1.vn
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant - Bitget
Intelligent Bio Solutions receives European patent for drug testing tech - Investing.com
Intelligent Bio Solutions receives European patent for drug testing tech By Investing.com - Investing.com India
A fingerprint sweat drug test just won its 8th European patent - stocktitan.net
Intelligent Bio Solutions Inc. Announces 2026 Restricted Stock Award Agreements and Incentive Plan Updates - Minichart
Intelligent Bio Solutions Grants Equity Awards, Updates ATM Capacity - The Globe and Mail
Intelligent Bio Solutions grants equity to CEO Harry Simeonidis and CFO Spiro Sakiris - TradingView
Intelligent Bio Solutions (NASDAQ: INBS) details new equity awards, ATM capacity - Stock Titan
INBS (NASDAQ: INBS) files ATM with Ladenburg to raise up to $3.97M - Stock Titan
If You Invested $1,000 in Intelligent Bio Solutions Inc (INBS) - Stock Titan
INBS (INBS) director receives 5,000 restricted shares in equity award - stocktitan.net
Intelligent Bio Solutions (NASDAQ: INBS) grants director 5,000 restricted shares - Stock Titan
INBS (INBS) CFO receives time- and performance-based restricted stock grants - Stock Titan
Director at Intelligent Bio Solutions (INBS) granted 5,000 shares - Stock Titan
Director at Intelligent Bio Solutions (INBS) awarded 5,000 restricted shares - Stock Titan
INBS (INBS) CEO receives time- and performance-based restricted stock grants - Stock Titan
Intelligent Bio Solutions Inc.: Fundamental Analysis and Financial Ratings | 12Q | US36151G7097 - marketscreener.com
Aug Setups: Is Intelligent Bio Solutions Inc part of any major index2026 Trends & Weekly Breakout Watchlists - baoquankhu1.vn
Why Is INBS Stock Rising Today? - Dailyhunt
Intelligent Bio Solutions Inc. (INBS) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Why Intelligent Bio Solutions Inc. stock is rated strong buyJuly 2025 Short Interest & Weekly High Return Stock Opportunities - Naître et grandir
How Intelligent Bio Solutions Inc. stock reacts to global recession fearsWeekly Profit Analysis & Target Return Focused Picks - Naître et grandir
Intelligent Bio Solutions announces reverse stock split - MSN
Jobs Data: Should you buy the dip on Intelligent Bio Solutions IncPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Why Did INBS Stock Fall 17% Today? - Stocktwits
Intelligent Bio Solutions Scales Manufacturing to Fuel Growth and U.S. Ambitions - AD HOC NEWS
HealthEquity (NASDAQ:HQY) & Intelligent Bio Solutions (NASDAQ:INBS) Head to Head Comparison - Defense World
Jobs Data: How cyclical is Intelligent Bio Solutions Incs revenue stream2025 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
INBS receives first reader shipment from Syrma Johari partnership By Investing.com - Investing.com Australia
INBS receives first reader shipment from Syrma Johari partnership - Investing.com
Intelligent Bio Solutions Expands Manufacturing Capacity and Deployment - TipRanks
Intelligent Bio Solutions Inc (INBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.72%
자본화:
|
볼륨(24시간):